Verastem, Inc.
VSTM · Pharmaceutical Preparations · 87.9M shares · -26%/yr ↓ buyback · EDGAR filings ↗
Reference price $4.18 · est. market cap ~$367M — last insider sale, 2026-06-22 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D47Newly commercial (AVMAPKI accelerated approval) but deeply loss-making against nascent revenue, with confirmatory data years away.
Strengths
- First FDA-approved therapy for KRAS-mutated recurrent LGSOC plus $205M cash and 209% revenue growth (90th pct) off launch
- Promising early VS-7375 (KRAS G12D) data with Fast Track designation
Risks
- ROE -3.66 (6th pct), net margin -6.8 (31st pct), interest coverage -149; cash funds only ~12 months
- Accelerated approval hinges on RAMP 301 confirmatory readout not due until mid-2027; only a terminated/unclear legacy trial posted
Notable findings
- No interest coverageInterest coverage -149.50 (cannot cover interest)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Net lossNet loss (net margin -677.6%)
- Buying back stockNet buyback — share count -26%/yr over 4y
- Strong balance sheetStrong balance sheet — $205M cash & investments
- Insider sellingInsider selling — 7 open-market sale(s) by 2 insider(s) (cluster of 2 insiders, last 6mo) Form 4 ↗
- Trial readout soonUpcoming trial readout ~2026-06 — PHASE1/PHASE2 · Non Small Cell Lung Cancer
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
- Notable holderHeld by 4 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +1 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-550.3%
Net margin
-677.6%
Return on equity
-366.2%
Return on assets
-85.0%
Revenue growth (QoQ)
6.5%
Interest coverage
-149.5×
Current ratio
3.1×
Tangible book value
$41M
Cash & investments
$205M
Stock comp / revenue
30.4%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-22 | Calkins Daniel | Sell | 4.0K | $4.18 |
| 2026-06-22 | Paterson Dan | Sell | 21K | $4.18 |
| 2026-06-22 | Calkins Daniel | Sell | 57 | $4.13 |
| 2026-05-21 | BAILEY MICHAEL P | Grant | 108K | — |
| 2026-05-21 | Tollefson Karin Anna | Grant | 36K | — |
| 2026-05-21 | Stuglik Brian M | Grant | 36K | — |
| 2026-05-21 | Rowinsky Eric K | Grant | 36K | — |
| 2026-05-21 | ROBERTSON MICHELLE | Grant | 36K | — |
| 2026-05-21 | Kapur Anil | Grant | 36K | — |
| 2026-05-21 | Bunn Paul A. | Grant | 36K | — |
| 2026-05-21 | JOHNSON JOHN | Grant | 36K | — |
| 2026-05-04 | Paterson Dan | Sell | 806 | $5.82 |
| 2026-03-20 | Calkins Daniel | Grant | 57 | $5.74 |
| 2026-02-04 | Paterson Dan | Sell | 970 | $6.69 |
| 2026-01-21 | Calkins Daniel | Grant | 17K | — |
| 2026-01-21 | Paterson Dan | Grant | 214K | — |
| 2026-01-12 | Paterson Dan | Sell | 10K | $7.16 |
| 2026-01-12 | Calkins Daniel | Sell | 5.0K | $7.16 |
| 2025-12-24 | Calkins Daniel | Sell | 80 | $7.86 |
| 2025-12-16 | Stuglik Brian M | Sell | 592 | $9.14 |
| 2025-12-16 | Paterson Dan | Sell | 393 | $9.14 |
| 2025-12-16 | Gagnon Robert E. | Sell | 283 | $9.14 |
| 2025-12-11 | Paterson Dan | Sell | 2.0K | $10.00 |
| 2025-12-10 | Paterson Dan | Sell | 2.0K | $10.07 |
| 2025-12-09 | Paterson Dan | Sell | 2.0K | $10.25 |
| 2025-12-08 | Paterson Dan | Sell | 2.0K | $10.50 |
| 2025-12-05 | Paterson Dan | Sell | 2.0K | $10.61 |
| 2025-12-04 | Paterson Dan | Sell | 2.0K | $10.00 |
| 2025-12-03 | Paterson Dan | Sell | 2.0K | $10.00 |
| 2025-12-02 | Paterson Dan | Sell | 2.0K | $10.32 |
| 2025-12-01 | Paterson Dan | Sell | 2.0K | $10.39 |
| 2025-11-28 | Paterson Dan | Sell | 2.0K | $10.79 |
| 2025-11-26 | Paterson Dan | Sell | 2.0K | $10.32 |
| 2025-11-25 | Paterson Dan | Sell | 2.0K | $10.00 |
| 2025-11-24 | Paterson Dan | Sell | 2.0K | $10.00 |
| 2025-11-21 | Bunn Paul A. | Sell | 6.2K | $10.00 |
| 2025-11-21 | Bunn Paul A. | Option exercise | 6.2K | $3.27 |
| 2025-11-21 | Kauffman Michael | Sell | 8.6K | $10.00 |
| 2025-11-21 | Paterson Dan | Sell | 2.0K | $10.00 |
| 2025-11-03 | Paterson Dan | Sell | 2.0K | $10.00 |
| 2025-11-03 | Paterson Dan | Sell | 1.3K | $9.35 |
| 2025-10-09 | Bunn Paul A. | Sell | 8.3K | $9.06 |
| 2025-09-24 | Calkins Daniel | Sell | 25 | $9.23 |
| 2025-09-22 | Calkins Daniel | Sell | 57 | $9.08 |
| 2025-09-16 | Stuglik Brian M | Sell | 587 | $9.99 |
| 2025-09-16 | Gagnon Robert E. | Sell | 281 | $9.99 |
| 2025-09-16 | Paterson Dan | Sell | 390 | $9.99 |
| 2025-08-06 | Paterson Dan | Sell | 1.3K | $5.81 |
| 2025-06-23 | Calkins Daniel | Sell | 25 | $4.71 |
| 2025-06-20 | Paterson Dan | Sell | 18K | $5.13 |
| 2025-06-20 | Calkins Daniel | Sell | 4.1K | $5.13 |
| 2025-06-16 | Paterson Dan | Sell | 335 | $5.65 |
| 2025-06-16 | Gagnon Robert E. | Sell | 284 | $5.65 |
| 2025-06-16 | Stuglik Brian M | Sell | 594 | $5.65 |
| 2025-05-22 | JOHNSON JOHN | Grant | 8.3K | — |
| 2025-05-22 | ROBERTSON MICHELLE | Grant | 8.3K | — |
| 2025-05-22 | Bunn Paul A. | Grant | 8.3K | — |
| 2025-05-22 | Kapur Anil | Grant | 8.3K | — |
| 2025-05-22 | Stuglik Brian M | Grant | 8.3K | — |
| 2025-05-22 | Gagnon Robert E. | Grant | 8.3K | — |
| 2025-05-22 | Kauffman Michael | Grant | 8.3K | — |
| 2025-05-22 | Tollefson Karin Anna | Grant | 8.3K | — |
| 2025-05-22 | Rowinsky Eric K | Grant | 8.3K | — |
| 2025-05-20 | Calkins Daniel | Sell | 11K | $8.13 |
| 2025-05-20 | Paterson Dan | Sell | 59K | $8.13 |
| 2025-05-16 | Paterson Dan | Grant | 150K | — |
| 2025-05-16 | Calkins Daniel | Grant | 39K | — |
| 2025-05-16 | Paterson Dan | Grant | 25K | — |
| 2025-05-05 | Paterson Dan | Sell | 820 | $7.30 |
| 2025-04-01 | Ros Matthew | Grant | 50K | — |
| 2025-03-24 | Calkins Daniel | Sell | 26 | $7.04 |
| 2025-03-20 | Calkins Daniel | Sell | 65 | $6.89 |
| 2025-03-17 | Paterson Dan | Sell | 244 | $6.95 |
| 2025-03-17 | Gagnon Robert E. | Sell | 284 | $6.95 |
| 2025-03-17 | Stuglik Brian M | Sell | 593 | $6.95 |
| 2025-02-04 | Paterson Dan | Sell | 858 | $5.70 |
| 2025-01-13 | Paterson Dan | Sell | 8.6K | $5.24 |
| 2025-01-10 | Paterson Dan | Grant | 100K | — |
| 2025-01-10 | Paterson Dan | Grant | 25K | — |
| 2025-01-10 | Calkins Daniel | Grant | 39K | — |
| 2025-01-06 | Calkins Daniel | Sell | 6 | $6.94 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07020221 ↗ | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer | PHASE1/PHASE2 | Recruiting | 2028-12-01 |
| NCT06072781 ↗ | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer Low Grade Serous Ovarian Cancer | PHASE3 | Recruiting | 2028-10-15 |
| NCT07644559 ↗ | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS | PHASE2 | Recruiting | 2027-06-01 |
| NCT05669482 ↗ | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer KRAS Activating Mutation, Metastatic Cancer | PHASE1/PHASE2 | Active Not Recruiting | 2026-08-31 |
| NCT05074810 ↗ | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients Non Small Cell Lung Cancer, KRAS Activating Mutation | PHASE1/PHASE2 | Active Not Recruiting | 2026-06-01 |
| NCT05375994 ↗ | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients Non Small Cell Lung Cancer, KRAS Activating Mutation | PHASE1/PHASE2 | Active Not Recruiting | 2025-12-24 |
| NCT06682572 ↗ | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients Low Grade Serous Ovarian Cancer, Ovarian Cancer | PHASE2 | Active Not Recruiting | 2025-12-01 |
| NCT04625270 ↗ | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | PHASE2 | Active Not Recruiting | 2024-11-15 |
| NCT07659782 ↗ | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer | PHASE2 | Not Yet Recruiting | 2027-06-01 |
| NCT07659795 ↗ | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer Colorectal Cancer | PHASE2 | Not Yet Recruiting | 2027-06-01 |
| NCT04620330 ↗ | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer Non Small Cell Lung Cancer, KRAS Activating Mutation | PHASE2 | Completed | 2023-08-29 |
| NCT05187169 ↗ | Food Effect of VS-6766 in Healthy Adult Subjects Food Effect | PHASE1 | Completed | 2022-04-12 |
| NCT02004028 ↗ | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants Malignant Pleural Mesothelioma | PHASE2 | Terminated | 2019-06-19 |
| NCT02943317 ↗ | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer Epithelial Ovarian Cancer | PHASE1 | Terminated | 2018-08-28 |
| NCT01849744 ↗ | Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies Non Hematologic Cancers, Metastatic Cancer | PHASE1 | Terminated | 2017-04-01 |
| NCT02651727 ↗ | Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects Pancreatic Cancer | PHASE1 | Terminated | 2017-01-01 |
| NCT01991938 ↗ | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma Non Hematologic Cancers, Metastatic Cancer | PHASE1 | Terminated | 2016-12-01 |
| NCT02215629 ↗ | Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | PHASE1 | Withdrawn | 2016-09-01 |
| NCT01951690 ↗ | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Non Small Cell Lung Cancer, Lung Cancer | PHASE2 | Completed | 2016-06-01 |
| NCT01870609 ↗ | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma | PHASE2 | Terminated | 2016-01-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-23 | 2026-06-23 | 0001104659-26-076809 ↗ |
| 8-K | 2026-06-17 | 2026-06-16 | 0001104659-26-074915 ↗ |
| 8-K | 2026-05-26 | 2026-05-21 | 0001104659-26-066026 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001104659-26-057126 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001104659-26-057114 ↗ |
| 10-K | 2026-03-04 | 2025-12-31 | 0001104659-26-023444 ↗ |
| 8-K | 2026-03-04 | 2026-03-04 | 0001104659-26-023462 ↗ |
| 8-K | 2026-02-04 | 2026-02-04 | 0001104659-26-010036 ↗ |
| 8-K | 2026-01-08 | 2026-01-08 | 0001104659-26-002135 ↗ |
| 8-K | 2025-12-31 | 2025-12-29 | 0001104659-25-125309 ↗ |
| 8-K | 2025-12-19 | 2025-12-15 | 0001104659-25-123295 ↗ |
| 8-K | 2025-11-17 | 2025-11-13 | 0001104659-25-112946 ↗ |